Q1 'very much a building quarter' for VolitionRx with growing cash reserves
The company reported a slower first quarter cash burn rate while growing cash reserves.
For the period ended March 31, it increased its cash and equivalents to US$14.3mln, compared to US$10.1mln in the previous quarter.
This week Volition entered into a sales and distribution partnership with Active Motif that will pave the way for the sale of a range of research-use-only (RUO) kits based on its proprietary Nucleosomics technology.
Quick facts: VolitionRx